Thus, bortezomib, being a reversible proteasome inhibitor with a short half-life, can be combined with other immunotherapies and may have major clinical implications to break tumor-induced tolerance in CD8+T cells and elicit a robust antitumor immune response in cancer patients with solid malignancies. This evidence concerns the gene CD8A and neoplasm.